Latest News From "The Pink Sheet" DAILY

Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine

Clovis takes over work on Clavis's pancreatic cancer drug and will develop a companion test to target patients who fare poorly on Lilly's current standard of care.   read more

 

DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks

Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.   read more

 

Merck Wins Second Fosamax Trial After Questioning Qualifications Of Expert Witness

After two bellwether cases, Merck has yet to lose and the next case involves a company-chosen defendant.   read more

 

Shire Seizes On Gaucher Opening With EMEA Filing For Velaglucerase

Given the shortage of Genzyme's Cerezyme treatment, European regulators decided to grant an accelerated review for Shire's medication.   read more

 

Pfizer Deal Will Help Propel Aurobindo's Revenues To $2 Billion In Three Years

Aurobindo's deal with Pfizer encompasses nearly 100 products, mostly tablets and capsules and a few injectables, to be sold in 70 geographies, including the U.S. and Europe..   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here